Key statistics
On Monday, Swedish Orphan Biovitrum AB (publ) (B6E:FRA) closed at 36.06, -7.73% below its 52-week high of 39.08, set on Feb 19, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 36.06 |
|---|---|
| High | 36.06 |
| Low | 36.06 |
| Bid | 36.08 |
| Offer | 36.42 |
| Previous close | 37.68 |
| Average volume | 254.00 |
|---|---|
| Shares outstanding | 357.41m |
| Free float | 197.59m |
| P/E (TTM) | 304.90 |
| Market cap | 141.32bn SEK |
| EPS (TTM) | 1.30 SEK |
Data delayed at least 15 minutes, as of Mar 02 2026 07:34 GMT.
More ▼
- Data presented at ACR Convergence 2025 highlight Sobi’s commitment to advancing care across rare and underserved inflammatory conditions
- Sobi Announces U.S. Food and Drug Administration Approves Doptelet® (avatrombopag) for the Treatment of Thrombocytopenia in Pediatric Patients One Year and Older with Persistent or Chronic Immune Thrombocytopenia (ITP)
